Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 1/20 | 0.56 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 6/20 | 0.46 |
| ▸ | BRD2 | P25440 | 2/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320773 | 0.84 | TDP2 (0.55) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL5829804 | 0.79 | CYP11B1 (0.55) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL5830094 | 0.78 | PIP4K2A (0.56) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| Acetic Acid SCHEMBL5831403 | 0.75 | PIP4K2A (0.48) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL5843496 | 0.75 | JAK2 (0.51) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL152990 | 0.74 | PIP4K2A (0.51) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL29899546 | 0.74 | PIP4K2A (0.51) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL6328529 | 0.73 | BRD4 (0.54) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL6320733 | 0.72 | CRBN (0.65) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL16090379 | 0.72 | BRD4 (0.52) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053086-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6635640-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1296975-A1 | 4-HETEROARYL-3-HETEROARYLIDENYL-2-INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-12 | — | — | US | disclosed |
| WO-2002002551-A1 | 4-HETEROARYL-3-HETEROARYLIDENYL-2-INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | PIP4K2A 266/4885PIP4K2B 270/4885CCNB2 285/4885 |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | PIP4K2A 266/4885PIP4K2B 270/4885CCNB2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.